SBIR-STTR Award

Development of analytical methods for glycosaminoglycans from biological sources
Award last edited on: 2/17/2024

Sponsored Program
SBIR
Awarding Agency
NIH : NIGMS
Total Award Amount
$2,277,542
Award Phase
2
Solicitation Topic Code
859
Principal Investigator
Vijayakanth Pagadala

Company Information

Glycan Therapeutics LLC (AKA: Glycan Therapeutics Corporation )

617 Hutton Street Suite 101
Raleigh, NC 27606
   (919) 977-1083
   info@glycantherapeutics.com
   www.glycantherapeutics.com
Location: Single
Congr. District: 02
County: Wake

Phase I

Contract Number: 1R43GM142304-01
Start Date: 9/15/2021    Completed: 9/16/2022
Phase I year
2021
Phase I Amount
$300,000
This SBIR phase I proposal is aimed at developing to develop a LC-MS/MS based method to analyze heparan sulfate in the sub-nanogram range. Heparan sulfate is a highly sulfated polysaccharide displaying a wide range of biological functions. There is a strong demand for a quantitative and sensitive method to analyze heparan sulfate. In this proposal, we propose to achieve the quantitation of heparan sulfate using the disaccharide analysis. To this end, heparan sulfate is depolymerized into eight disaccharides by heparin lyases. The composition analysis of the resultant disaccharides is accomplished by a LC-MS/MS method. The crucial innovation in our proposed method is to add "absolute quantitation" capability using eight 13C-labeled disaccharide calibrants and one 13C-labeled polysaccharide calibrant. Aim 1 is designed to demonstrate the ability to quantitative compositional analysis of heparan sulfate from mouse tissues and plasma. In phase I studies, we will focus on analyzing the HS from plasma, lung, liver, and kidney from healthy mice and burn injury mice. Aim 2 is aimed to conduct quantitative analysis of heparan sulfate from a single histological slide. The sensitivity of the LC-MS/MS method will be improved. In the phase I studies, we will analyze the heparan sulfate from histological slides from lung, liver, and kidney from healthy and burn injury mice. In the phase II studies, we plan to expand the analysis of heparan sulfate to all mouse tissues from healthy mice and four disease mice. We also plan to conduct the analysis from clinical samples from burn patients and sepsis patients in phase II studies. The success of this project will provide a method to analyze heparan sulfate with sensitivity and accuracy for biologists and will be a major break-through in glycobiology research.

Public Health Relevance Statement:
Project Narrative Heparan sulfate is a sulfated polysaccharide displaying a wide range of biological functions. In this project, Glycan Therapeutics plans to develop an innovative method to analyze heparan sulfate from biological sources. The success of the project will provide a new tool to investigate the biological roles of this essential polysaccharide to advance glycoscience research.

Project Terms:
Animals; Blood coagulation; Blood Clotting; Burn injury; Burns; burned; Cell Differentiation process; Cell Differentiation; Liquid Chromatography; Communities; Disaccharides; Disease; Disorder; Embryonic Development; Embryo Development; Embryogenesis; Goals; Heparitin Sulfate; Heparan Sulfate; Institutes; Kidney; Kidney Urinary System; renal; Liver; hepatic body system; hepatic organ system; Lung; Lung Respiratory System; pulmonary; Methods; Mus; Mice; Mice Mammals; Murine; North Carolina; Oligosaccharides; Legal patent; Patents; Patients; Plasma; Blood Plasma; Plasma Serum; Reticuloendothelial System, Serum, Plasma; Play; Polysaccharides; Glycans; Publishing; quinoline; Reagent; Research; Role; social role; Technology; Time; Tissues; Body Tissues; Universities; Heparin Lyase; Heparin Eliminase; Heparinase; Heparinase I; Neutralase; base; Label; improved; Clinical; Phase; Biological; Ensure; Individual; Recovery; Licensing; Measurement; Biological Process; Biological Function; Collaborations; depolymerization; Therapeutic; tool; Slide; Source; Techniques; Sulfate; Viral; Services; success; Structure; Negotiating; Negotiation; Mediation; Sampling; Inflammatory Response; Glycobiology; Measurable; in vivo; Small Business Innovation Research Grant; SBIR; Small Business Innovation Research; Monitor; Principal Investigator; mass spectrometer; design; designing; Coupled; innovation; innovate; innovative; phase 1 study; Phase I Study; phase 2 study; phase II study; histological slides; histologic slides; experimental study; experiment; experimental research; septic patients; sepsis patients

Phase II

Contract Number: 2R44GM142304-02
Start Date: 9/15/2021    Completed: 8/31/2024
Phase II year
2022
(last award dollars: 2023)
Phase II Amount
$1,977,542

This SBIR phase II proposal is aimed to develop a LC-MS/MS based method to analyze heparan sulfate and chondroitin sulfate with sub-nanogram quantities. Heparan sulfate and chondroitin sulfate are highly sulfated polysaccharides displaying a wide range of biological functions. There is a strong demand for a quantitative and sensitive method to analyze heparan sulfate and chondroitin sulfate. In this proposal, we propose to achieve the quantitation of heparan sulfate and chondroitin sulfate using 13C-labeled calibrants. To this end, heparan sulfate and chondroitin sulfate are depolymerized into disaccharides by heparin lyases and chondroitin ABCase. The composition analysis of the resultant disaccharides is accomplished by a LC-MS/MS method. In addition, we plan to use 13C-labeled heparan sulfate octasaccharide calibrants to determine the levels of 3-O-sulfated heparan sulfate. The crucial innovation in our proposed method is to add "absolute quantitation" capability using 13C-labeled disaccharide calibrants and 13C-labeled octasaccharide calibrants. Aim 1 is designed to demonstrate the ability to quantitative the level of 3-O-sulfated heparan sulfate. We will focus on analyzing the analysis of 3-O-suflated heparan sulfate from plasma samples and from human brain tissues with neurodegenerative diseases. Aim 2 is aimed to develop a method for quantitative disaccharide analysis of chondroitin sulfate. We will synthesize six 13C- labeled chondroitin sulfate disaccharide calibrants to carry out the studies. We will also conduct the analysis for chondroitin sulfate from human brain tissues from neurodegenerative diseases. The completed heparan sulfate and chondroitin sulfate analysis from plasma and solid tissues will demonstrate the robustness of the method. The success of this project will provide a method to analyze heparan sulfate and chondroitin sulfate with sensitivity and accuracy for biologists.

Public Health Relevance Statement:
Project Narrative Heparan sulfate and chondroitin sulfate are sulfated polysaccharides displaying a wide range of biological functions. In this project, Glycan Therapeutics plans to develop an innovative method to analyze heparan sulfate and chondroitin sulfate from biological sources. The success of the project will provide a new tool to investigate biological roles of this essential polysaccharide to advance glycoscience research.

Project Terms:
Animals; Biomedical Research; Blood coagulation; Blood Clotting; Brain; Brain Nervous System; Encephalon; Cell Differentiation process; Cell Differentiation; Chondroitin; Chondroitin Sulfates; hydrogen sulfate Chondroitin; Clinical Trials; Disaccharides; Embryonic Development; Embryo Development; Embryogenesis; Enzymes; Enzyme Gene; Glycosaminoglycans; Mucopolysaccharides; Goals; Growth; Generalized Growth; Tissue Growth; ontogeny; Heparin; Heparinic Acid; Low-Molecular-Weight Heparin; LMWH; Heparitin Sulfate; Heparan Sulfate; Human; Modern Man; Income; Economic Income; Economical Income; Methods; Mus; Mice; Mice Mammals; Murine; Metastasis; Metastasize; Metastatic Lesion; Metastatic Mass; Metastatic Neoplasm; Metastatic Tumor; Secondary Neoplasm; Secondary Tumor; cancer metastasis; tumor cell metastasis; Neoplasm Metastasis; Nerve Cells; Nerve Unit; Neural Cell; Neurocyte; neuronal; Neurons; North Carolina; Oligosaccharides; Patients; Blood Plasma; Plasma Serum; Reticuloendothelial System, Serum, Plasma; Plasma; Glycans; Polysaccharides; quinoline; Research; mRNA; Messenger RNA; social role; Role; Sales; Time; Tissues; Body Tissues; Universities; Work; Heparin Lyase; Heparin Eliminase; Heparinase; Heparinase I; Neutralase; Businesses; Injury; injuries; analytical method; base; dosage; quality assurance; Label; improved; Solid; Phase; Biological; biologic; Series; Biological Function; Biological Process; Letters; depolymerization; Therapeutic; tool; Reaction; subdermal; subcutaneous; Source; brain tissue; Sulfate; Viral; Degenerative Neurologic Diseases; Degenerative Neurologic Disorders; Nervous System Degenerative Diseases; Neural Degenerative Diseases; Neural degenerative Disorders; Neurodegenerative Diseases; Neurologic Degenerative Conditions; degenerative diseases of motor and sensory neurons; degenerative neurological diseases; neurodegenerative illness; Neurodegenerative Disorders; Services; experience; success; Structure; Reporting; parasite infection; Parasitic infection; Sampling; Inflammatory Response; Measurable; Resolution; in vivo; Small Business Innovation Research Grant; SBIR; Small Business Innovation Research; Validation; trend; Modification; Tracer; Development; developmental; design; designing; innovation; innovate; innovative; mouse model; murine model; disease diagnosis; phase 1 study; Phase I Study; phase 2 study; phase II study; experimental study; experiment; experimental research; cost estimate; cost estimation; diagnostic tool